Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 single and multiple ascending dose study of AZP-3813 in healthy subjects
NL-OMON59518Phase 1Completed
- Sponsor
- Amolyt Pharma
- Start
- May 2023
- Modality
- Cyclic Peptides → Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 1 trial of AZP-3813 in acromegaly, sponsored by Amolyt Pharma. Started May 2023; status: completed.
02
Drugs
AZP-3813
03
Conditions
acromegaly
Beyond the preview
Go deeper on NL-OMON59518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59518.